{"title":"免疫修饰格拉斯哥预后评分在纳武单抗治疗头颈部鳞状细胞癌患者中的预测价值。","authors":"Toshimitsu Ohashi, Nansei Yamada, Kosuke Terazawa, Hirofumi Shibata, Masato Takiwaki, Takanori Wakaoka, Shigeaki Tanahasi, Hiroki Takahashi, Bunya Kuze, Masami Ohnishi, Hiromichi Shirato, Keisuke Mizuta, Takenori Ogawa","doi":"10.1017/S0022215125102612","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The immune-modified Glasgow Prognostic Score, encompassing C-reactive protein, serum albumin, and lymphocyte count, is a valuable prognostic tool for head and neck squamous cell carcinoma. We aimed to assess the utility of immune-modified Glasgow Prognostic Score in predicting the treatment response to nivolumab in patients with head and neck squamous cell carcinoma.</p><p><strong>Methods: </strong>Seventy-six patients with head and neck squamous cell carcinoma treated with nivolumab were included in this study. The imGPS was assessed before the initial nivolumab dose and four weeks after immune-modified Glasgow Prognostic Score.</p><p><strong>Results: </strong>Multivariable analysis identified four weeks after immune-modified Glasgow Prognostic Score as an adverse prognostic factor for progression-free and overall survival. The best overall response was significantly associated with four weeks after immune-modified Glasgow Prognostic Score. Remarkably, all patients with four weeks after immune-modified Glasgow Prognostic Score = 3 and 8 (80.0%) of 10 patients with four weeks after immune-modified Glasgow Prognostic Score = 2 experienced progressive disease.</p><p><strong>Conclusion: </strong>The immune-modified Glasgow Prognostic Score proves valuable for predicting prognosis in patients with head and neck squamous cell carcinoma undergoing nivolumab treatment, particularly excelling in identifying individuals unlikely to respond to nivolumab.</p>","PeriodicalId":16293,"journal":{"name":"Journal of Laryngology and Otology","volume":" ","pages":"1-7"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictive value of immune-modified Glasgow prognostic score in patients with head and neck squamous cell carcinoma treated with nivolumab.\",\"authors\":\"Toshimitsu Ohashi, Nansei Yamada, Kosuke Terazawa, Hirofumi Shibata, Masato Takiwaki, Takanori Wakaoka, Shigeaki Tanahasi, Hiroki Takahashi, Bunya Kuze, Masami Ohnishi, Hiromichi Shirato, Keisuke Mizuta, Takenori Ogawa\",\"doi\":\"10.1017/S0022215125102612\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The immune-modified Glasgow Prognostic Score, encompassing C-reactive protein, serum albumin, and lymphocyte count, is a valuable prognostic tool for head and neck squamous cell carcinoma. We aimed to assess the utility of immune-modified Glasgow Prognostic Score in predicting the treatment response to nivolumab in patients with head and neck squamous cell carcinoma.</p><p><strong>Methods: </strong>Seventy-six patients with head and neck squamous cell carcinoma treated with nivolumab were included in this study. The imGPS was assessed before the initial nivolumab dose and four weeks after immune-modified Glasgow Prognostic Score.</p><p><strong>Results: </strong>Multivariable analysis identified four weeks after immune-modified Glasgow Prognostic Score as an adverse prognostic factor for progression-free and overall survival. The best overall response was significantly associated with four weeks after immune-modified Glasgow Prognostic Score. Remarkably, all patients with four weeks after immune-modified Glasgow Prognostic Score = 3 and 8 (80.0%) of 10 patients with four weeks after immune-modified Glasgow Prognostic Score = 2 experienced progressive disease.</p><p><strong>Conclusion: </strong>The immune-modified Glasgow Prognostic Score proves valuable for predicting prognosis in patients with head and neck squamous cell carcinoma undergoing nivolumab treatment, particularly excelling in identifying individuals unlikely to respond to nivolumab.</p>\",\"PeriodicalId\":16293,\"journal\":{\"name\":\"Journal of Laryngology and Otology\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Laryngology and Otology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/S0022215125102612\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Laryngology and Otology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0022215125102612","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Predictive value of immune-modified Glasgow prognostic score in patients with head and neck squamous cell carcinoma treated with nivolumab.
Objectives: The immune-modified Glasgow Prognostic Score, encompassing C-reactive protein, serum albumin, and lymphocyte count, is a valuable prognostic tool for head and neck squamous cell carcinoma. We aimed to assess the utility of immune-modified Glasgow Prognostic Score in predicting the treatment response to nivolumab in patients with head and neck squamous cell carcinoma.
Methods: Seventy-six patients with head and neck squamous cell carcinoma treated with nivolumab were included in this study. The imGPS was assessed before the initial nivolumab dose and four weeks after immune-modified Glasgow Prognostic Score.
Results: Multivariable analysis identified four weeks after immune-modified Glasgow Prognostic Score as an adverse prognostic factor for progression-free and overall survival. The best overall response was significantly associated with four weeks after immune-modified Glasgow Prognostic Score. Remarkably, all patients with four weeks after immune-modified Glasgow Prognostic Score = 3 and 8 (80.0%) of 10 patients with four weeks after immune-modified Glasgow Prognostic Score = 2 experienced progressive disease.
Conclusion: The immune-modified Glasgow Prognostic Score proves valuable for predicting prognosis in patients with head and neck squamous cell carcinoma undergoing nivolumab treatment, particularly excelling in identifying individuals unlikely to respond to nivolumab.
期刊介绍：
The Journal of Laryngology & Otology (JLO) is a leading, monthly journal containing original scientific articles and clinical records in otology, rhinology, laryngology and related specialties. Founded in 1887, JLO is absorbing reading for ENT specialists and trainees. The journal has an international outlook with contributions from around the world, relevant to all specialists in this area regardless of the country in which they practise. JLO contains main articles (original, review and historical), case reports and short reports as well as radiology, pathology or oncology in focus, a selection of abstracts, book reviews, letters to the editor, general notes and calendar, operative surgery techniques, and occasional supplements. It is fully illustrated and has become a definitive reference source in this fast-moving subject area. Published monthly an annual subscription is excellent value for money. Included in the subscription is access to the JLO interactive web site with searchable abstract database of the journal archive back to 1887.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
